Search clinical trials for: ImmunoGen

Total 3615 results

Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
Nabi Biopharmaceuticals
Public Health England

Completed

StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery

Staphylococcal Infections

United Kingdom
Nabi Biopharmaceuticals

Completed

StaphVAX Immunogenicity in Orthopedic Implant Patients

Staphylococcal Infections | Joint Prosthesis

United States
MedImmune LLC

Completed

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Influenza

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Prevenar Immunogenicity in High Risk Children

Vaccines, Pneumococcal Conjugate Vaccine
Epimmune
Pharmexa A/S; Pharmexa-Epimmune

Unknown

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART) (EP1090)

HIV Infections

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Meningitis, Meningococcal

Australia
MedImmune LLC

Completed

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

Healthy

United States
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

Prevention | Pandemic Influenza
Queen Elizabeth II Health Sciences Centre

Unknown

The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

Pertussis
Johann Wolfgang Goethe University Hospital
Allergopharma GmbH & Co. KG

Completed

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

Immunotherapy

Germany
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Melanoma

Germany
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Malignant Melanoma

Switzerland
European Malaria Vaccine Initiative

Unknown

GMZ2-Aluminum Hydroxide Phase I, Tübingen

Malaria

Germany
Norwegian Institute of Public Health

Completed

Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine

Pertussis | Tetanus | Diphtheria | Polio

Norway
University of Oxford

Completed

A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers

TB

United Kingdom
University of Oxford

Completed

Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.

Tuberculosis

United Kingdom
University of Oxford

Completed

A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers

TB

United Kingdom
Seoul National University Hospital
HK inno.N Corporation

Completed

Safety and Immunogenicity of CJ-50300

Smallpox

Korea, Republic of
Centers for Disease Control and Prevention
Southcentral Foundation; Alaska Native Tribal Health Consortium

Completed

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders

Pneumococcal Infections

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects

Influenza

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Pandemic Influenza Disease

Italy
Novartis
Novartis Vaccines

Completed

Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults

Encephalitis, Tick-Borne

Germany
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

Prevention of Meningococcal Infection

Italy
European Malaria Vaccine Initiative
University of Oxford; Wellcome Trust

Completed

Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

Malaria | Malaria, Falciparum

United Kingdom
PowderMed

Completed

Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu

Influenza (Pandemic)

United Kingdom
PowderMed

Completed

Study of the Ability of a Flu Vaccine to Prevent Flu Infection

Influenza

United Kingdom
University of Oxford

Completed

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG

Tuberculosis

United Kingdom
University of Oxford

Completed

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously

Tuberculosis

United Kingdom
ID Biomedical Corporation, Quebec

Completed

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

Influenza

United States
University of Oxford

Completed

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

Tuberculosis

United Kingdom
University of Oxford

Completed

A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers

Tuberculosis

Gambia
VaxGen

Unknown

Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers

Smallpox

United States
The Cleveland Clinic

Completed

Influenza Vaccination in Bone Marrow Transplantation

Influenza

United States
ID Biomedical Corporation, Quebec

Unknown

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

Influenza

United States
Corixa Corporation

Unknown

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Swiss Tropical & Public Health Institute

Terminated

Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides

Falciparum Malaria
International Vaccine Institute
Göteborg University; National Institute of Hygiene and Epidemiology, Vietnam

Completed

Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine

Cholera

Vietnam
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

Meningococcal Infection

Germany
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children

Healthy

Philippines, Thailand
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older

Influenza

Italy
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months

Influenza

Finland
Novartis
Novartis Vaccines; Chiron s.r.l. Beijing Representative Office

Completed

Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)

Influenza

China
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects

Influenza

Italy
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.

Influenza Disease

Italy
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.

Influenza

Italy
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.

Pneumococcal Infections

France
Bavarian Nordic

Completed

Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects

Smallpox

Germany
University of Oslo School of Pharmacy

Completed

Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk

Renal Transplant Recipients

3

Subscribe